TB-500

Overview

TB-500 is a synthetic version of thymosin beta-4 (Tβ4), a 43-amino acid protein naturally occurring in virtually all human and animal cells. Thymosin beta-4 was originally isolated from the thymus gland and has been identified as the primary intracellular G-actin sequestering peptide. Its role in actin dynamics makes it central to cellular processes including migration, differentiation, and tissue repair. TB-500 contains the active region of Tβ4 responsible for actin binding and cell migration promotion. Published research spans cardiac, dermal, ocular, and neurological tissue repair in animal models, with some clinical investigations in corneal healing.

For research use only · Not FDA/EMA approved · Not for human consumption

Mechanism of Action

TB-500 functions primarily through interaction with the actin cytoskeleton. Published research describes its binding to G-actin monomers, preventing polymerization and promoting cell motility. The active sequence Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline) has been identified as a key mediator of its biological activities. Studies describe promotion of angiogenesis, reduction of inflammatory cytokine expression, upregulation of laminin-5 and other extracellular matrix proteins, and modulation of metalloproteinase activity. In cardiac research, Tβ4 has been reported to activate resident progenitor cells and reduce scar formation following experimental myocardial infarction.

For research use only · Not FDA/EMA approved · Not for human consumption

Key Research Areas

• Cardiac repair and cardioprotection in rodent MI models
• Wound healing acceleration and dermal tissue regeneration
• Corneal epithelial repair and ocular surface healing
• Anti-inflammatory and anti-fibrotic effects in tissue models
• Actin dynamics and cellular migration mechanisms
• Neuronal survival and CNS repair in preclinical models
• Hair follicle stem cell activation in animal studies

For research use only · Not FDA/EMA approved · Not for human consumption

Published Studies (7 cited)

For research use only · Not FDA/EMA approved · Not for human consumption

Dosage in Published Research

Published animal studies have administered TB-500/Tβ4 at doses ranging from 6 mg/kg to 150 μg/animal in rodent models, via intraperitoneal, subcutaneous, or topical routes depending on the model. Cardiac repair studies typically used systemic administration, while wound healing studies have utilized both systemic and local application. Clinical eye studies used topical formulations. All dosing derived from published literature only.

For research use only · Not FDA/EMA approved · Not for human consumption

Storage & Handling

Store lyophilized TB-500 at -20°C. Reconstituted peptide should be stored at 2–8°C and used within 14 days. Protect from light and avoid repeated freeze-thaw cycles. Handle with sterile technique.

For research use only · Not FDA/EMA approved · Not for human consumption

Safety Profile (Literature Only)

Published preclinical studies report no significant toxicity at investigated doses. Tβ4 is a naturally occurring protein present in all nucleated cells. Clinical trials for corneal healing (RegeneRx Biopharmaceuticals) have reported acceptable safety profiles in published data. No comprehensive toxicology studies establishing safety in systemic human use have been published. This compound is for laboratory research use only.

For research use only · Not FDA/EMA approved · Not for human consumption